Kalaris Therapeutics, Inc. KLRS
2.12 USD +0.07 (+3.41%)
Nov 4, 2026, 2:44 PM EST
2.03 Day range 2.14
1.78 52-week range 11.88
- YTD
- -74.88%
- 1 year
- -54.99%
- Market cap
- 50.94M
- EPS (ttm)
- -2.02
- YTD return
- -74.88%
- 1-year return
- -54.99%
- Volume
- 19.90K
- Avg volume
- 65.41K
- Open
- 2.03
- Previous close
- 2.05
- Day's range
- 2.03 – 2.14
- 52-week range
- 1.78 – 11.88
2Y -18.26 (-89.51%)
Financials — quick view
KLRS Revenue — quarterly 0
KLRS Net income — quarterly -11.52M
KLRS EPS — quarterly -0.48
News
Alpha Buying: 3 Beaten-Down Biotech Stocks Backed by a Specialist Investor 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Stock Has Average Price Target of $18.75 
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference 
Kalaris Therapeutics Q2 EPS $(0.48) Beats $(0.49) Estimate 
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates 
Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4% – Here’s What Happened 
KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders - Kalaris Therapeutics Appoints Liisa Bayko CFO
Your note
Sign in to keep a note on KLRS — it syncs with the Stock Master app.